CV Sciences Inc (CVSI) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of CV Sciences Inc $0.04, price $0.01, upside +207.7%, quality 39 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch CV Sciences Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 25, 2026.
How to read this chart
60‑month range $0.0100 – $0.4100 · fair‑value band $0.0300 – $0.0500 · the $0.0130 price screens below the $0.0400 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Jun 25, 2026.
Follow CV Sciences in your weekly email
Every Wednesday you see whether CV Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
CV Sciences, Inc. engages in the development, manufacture, marketing, and sale of herbal supplements, hemp-based cannabidiol (CBD), and plant-based food products in North America.
Show more
CV Sciences, Inc. engages in the development, manufacture, marketing, and sale of herbal supplements, hemp-based cannabidiol (CBD), and plant-based food products in North America. It offers its products under the PlusCBD, PlusCBD Pet, PlusHLTH, Cultured Foods, and Lunar Fox brand names in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, select distributors, brick and mortar retailers, and select e-tailers. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.
Stock analysis
CV Sciences Inc (CVSI) currently trades at $0.0130, while our model-based Fair Value estimate is $0.0400, implying the stock looks roughly 67.5% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $0.0300 (bear) to $0.0500 (bull), the price of $0.0130 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
CV Sciences Inc reported revenue of $13.8M in FY2025 versus $20.0M in FY2021, a compound −8.9%/yr. Reported net income was −$958K in FY2025.
Key figures
Market cap $4.1M · P/S ratio 0.30 · EPS (TTM) $−0.0100 · Net margin −6.9% · Return on equity −88.0% · Return on assets (EBIT) −30.7% · Operating margin −10.0% · Revenue (TTM) $13.4M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).
What moves the price
The share trades about 86% below its 52-week high and 30% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 208%, CVSI screens cheaper than that median.
Fair Value models
Bear $0.0300Fair Value $0.0400Bull $0.0500
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−12.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.8%
Start year 2020 (pandemic). Over 10 years: +1.8% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−92.5% (2020) → −3.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 630 stocks
Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score38 · Bottom 25%
Fair Value upside+200% · Top 25%
Profitability
Return on assets−7% · Bottom 25%
Net margin (TTM)−11% · Bottom 25%
Operating margin (TTM)−10% · Bottom 25%
Growth and dividend
Revenue growth−11% · Bottom 25%
Balance sheet
Debt / equity0.99× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is CV Sciences Inc (CVSI) overvalued or undervalued?
As of Jun 25, 2026, our model estimates a fair value of $0.0400 versus a price of $0.0130, about +208% upside (undervalued).
What is the fair value of CVSI?
Our model-based fair value for CV Sciences Inc is $0.0400 (as of Jun 25, 2026), built from audited fundamentals. The current price: $0.0130.
What is the quality score of CVSI?
CV Sciences Inc has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CV Sciences Inc (CVSI)?
Our model-based price target is the fair value of $0.0400 (as of Jun 25, 2026) from 1 valuation models. Cautious scenario $0.0300, optimistic scenario $0.0500. It is a calculation from audited fundamentals, not an analyst target.
What is the CV Sciences Inc stock forecast for 2026?
Our models put fair value at $0.0400, about +208% upside versus a price of $0.0130 (undervalued). Cautious scenario $0.0300, optimistic scenario $0.0500. The calculation is refreshed regularly with new filings.
What is the revenue of CV Sciences Inc (CVSI)?
CV Sciences Inc reported trailing-twelve-month revenue of about $13.4M (latest available figure, as of Jun 25, 2026).
What is the intrinsic value of CV Sciences Inc (CVSI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CV Sciences Inc it is $0.0400 per share (as of Jun 25, 2026), against a price of $0.0130. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is CV Sciences Inc stock overvalued or undervalued in 2026?
As of Jun 25, 2026, CVSI trades below its calculated fair value: price $0.0130, fair value $0.0400, a gap of about +208% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CVSI?
No. The price is what the market pays today ($0.0130); the fair value is what the company's own numbers justify ($0.0400). For CV Sciences Inc the two are $0.0270 per share apart. That gap is exactly why we show both numbers side by side.
How much is CV Sciences Inc worth?
The market values CV Sciences Inc at about $4.1M (market capitalisation, as of Jun 25, 2026). Per share that is $0.0130; our models calculate a fair value of $0.0400 per share.
What do the bullish and bearish scenarios say about CVSI?
Our models span a range for CV Sciences Inc: cautious scenario $0.0300, base $0.0400, optimistic $0.0500 per share (as of Jun 25, 2026, price $0.0130). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CV Sciences Inc (CVSI)?
Balance-sheet figures for CV Sciences Inc (as of Jun 25, 2026): return on equity −88.0%, debt of 0.99 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is CVSI from its 52-week high?
CV Sciences Inc trades at $0.0130, about 86% below its 52-week high of $0.0900 and 30% above the low of $0.0100 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0400 is for.
Which stocks are comparable to CV Sciences Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CV Sciences Inc stock attractive at the current price?
The data as of Jun 25, 2026: price $0.0130, calculated fair value $0.0400 (+208%), Quality Score 39/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CVSI calculated?
We run CV Sciences Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0400, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. CV Sciences Inc currently trades 208 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CV Sciences Inc (CVSI)?
The closing price on Sep 23, 2026 was $0.0130. Our model-based fair value is $0.0400, about +208% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CV Sciences Inc right now?
The large discount to fair value meets weak quality (39/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($0.0300). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of CV Sciences Inc
How large is the market capitalisation of CV Sciences Inc (CVSI)?
The market capitalisation of CV Sciences Inc is $4.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CV Sciences Inc (CVSI)?
The price-to-sales ratio of CV Sciences Inc is 0.30 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CV Sciences Inc (CVSI)?
Earnings per share at CV Sciences Inc are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of CV Sciences Inc (CVSI)?
The net margin of CV Sciences Inc is −6.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CV Sciences Inc (CVSI)?
The return on equity (ROE) of CV Sciences Inc is −88.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CV Sciences Inc (CVSI)?
On an EBIT basis the return on assets of CV Sciences Inc is −30.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CV Sciences Inc (CVSI)?
The operating margin of CV Sciences Inc is −10.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CV Sciences Inc (CVSI)?
Revenue at CV Sciences Inc is growing −11.4% versus a year earlier (3y avg −5.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does CV Sciences Inc (CVSI) generate?
The free cash flow of CV Sciences Inc is −$516K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does CV Sciences Inc (CVSI) carry?
The net debt of CV Sciences Inc is $984K (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch CV Sciences Inc in the live analysis
One click puts CV Sciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Jun 25, 2026